ABSTRACT
Objective There is a need for comparable worldwide data on the impact of diabetes on mortality. This study assessed diabetes and all-cause mortality among middle-aged and older adults in five countries.
Research Design and Methods We analyzed adults aged 51 years or older followed between 2010 and 2020 from population-based cohorts in China, England, Mexico, rural South Africa, and the United States. Diabetes was defined by self-report or an elevated diabetes blood-based biomarker meeting the clinical criteria for diabetes. All-cause mortality was assessed through linkages or informant interviews. We used Poisson regression models to estimate mortality rate ratios and mortality rate differences, comparing people with diabetes to those without diabetes. Models were adjusted for age, gender, education, smoking status, body mass index, and economic status.
Results We included 29,397 individuals, of whom 4,916 (16.7%) died during the study period. The median follow-up time ranged from 4.6 years in South Africa to 8.3 years in China. The adjusted all-cause mortality rate ratios for people with diabetes versus those without diabetes ranged from 1.53 (95% CI: 1.39-1.68) in the United States to 2.02 (95% CI: 1.34-3.06) in Mexico. The adjusted mortality rate differences (per 1,000 person-years) for people with diabetes versus those without diabetes ranged from 11.9 (95% CI: 4.8-18.9) in England to 24.6 (95% CI: 12.2-37.0) in South Africa.
Conclusions Diabetes was associated with increased all-cause mortality in population-based cohorts across five diverse countries. There is an urgent need to implement clinical and public health interventions to improve diabetes outcomes globally.
Why did we undertake this study?We aimed to address the need for comparable estimates of all-cause mortality among people with diabetes in diverse global settings.
What is the specific question(s) we wanted to answer?How does diabetes impact all-cause mortality among middle-aged and older adults (aged 51 years or greater) in China, England, Mexico, rural South Africa, and the United States?
What did we find?Middle-aged and older adults with diabetes had higher all-cause mortality than people without diabetes in all countries. Relative mortality differences ranged from mortality rate ratios of 1.53 in the United States to 2.02 in Mexico. Absolute mortality differences ranged from mortality rate differences (per 1,000 person-years) of 11.9 in England to 24.6 in South Africa.
What are the implications of our findings?There is an urgent need to implement clinical and public health interventions to improve diabetes outcomes globally.
Competing Interest Statement
D.F. and JM.-G. have received consultant fees from the World Health Organization for activities relating to global diabetes monitoring.
Funding Statement
The preparation of this paper was supported by the Gateway to Global Aging Data, which is funded by the U.S. National Institute on Aging (award R01AG030153). The English Longitudinal Study of Ageing is funded by the National Institute on Aging (award R01AG017644) and by a consortium of U.K. government departments (Department for Health and Social Care; Department for Transport; and Department for Work and Pensions, which is coordinated by the National Institute for Health Research [NIHR, Ref: 198-1074]). The Health and Retirement Study is funded by the U.S. National Institute on Aging (award U01AG009740) and the Social Security Administration, and performed at the Institute for Social Research, University of Michigan. The Health and Aging in Africa: A Longitudinal Study in South Africa study is funded by the U.S. National Institute on Aging (award 5P01AG041710). D.F. was supported by the U.S. National Heart, Lung, and Blood Institute (award K23HL161271), the Michigan Center for Diabetes Translational Research (award P30DK092926), the University of Michigan Claude D. Pepper Older Americans Independence Center (award 5P30AG024824), and the University of Michigan Caswell Diabetes Institute Clinical Translational Research Scholars Program. Y.S.Z was supported by the U.S. National Institute on Aging (award R00AG070274). JM-G is supported by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (award number K23DK12516). The contents of this research are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was deemed exempt from institutional ethics approval at the University of Michigan (HUM00256096).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Denotes joint senior authors
